



ORIGINAL RESEARCH ARTICLE

Acute and Sub-Acute Toxicity Studies of Aqueous Leaf Extract of *Launaea taraxacifolia* (Willd.) in Wistar Rats

UMARU MILLICENT LADI¹

ABUBAKAR KABIRU¹

UYAIABASI GABRIEL NOBLEFATHER^{2*}

TIJJANI RABIU GIAZE¹

ALKALI YUSUF IBRAHIM¹

ADEBISI IYABO MOBOLAWA¹

ALEBIOSU OLURANTI CELESTINA³

SAHABI SODDIK MALAMI⁴

ABDULLAHI SULEIMAN¹

HALILU MSHELIA EMMANUEL⁵

¹Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria;

²Department of Pharmacology, Faculty of Basic Clinical Sciences, Benjamin S. Carson (Snr) School of Medicine, Babcock University, Ogun, Nigeria;

³Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria;

⁴Department of Pathology, College of Health Sciences, Usmanu University, Sokoto, Nigeria;

⁵Department of Pharmacognosy and Ethnopharmacy, Faculty of Pharmaceutical Science, Usmanu Danfodiyo University, Sokoto, Nigeria

*Corresponding Author: Uyaiabasi Gabriel Noblefather Department of Pharmacology, Faculty of Basic Clinical Sciences, Benjamin S. Carson (Snr) School of Medicine, Babcock University, Ogun Nigeria, Ilishan 121103. E-mail: noblefather@gmail.com

ABSTRACT

Aim: This study aimed to evaluate the acute and sub-acute toxicity profile of aqueous leaf extract of *Launaea taraxacifolia* in Wistar rats.

Methods: Acute toxicity was investigated using Lorke's method, while sub-acute toxicity was assessed using the Organisation for Economic Co-operation and Development guideline. The first phase of the acute toxicity study had nine Wistar rats randomly divided into three groups (n = 3) and administered doses of 10, 100 and 1000mg/kg (orally [po]) leaf extract of LT, respectively. In the second phase, four groups (n = 1) received doses of 1200, 1600, 2900 and 5000 mg/kg (po) of the extract, respectively. For the sub-acute toxicity study, 20 rats were randomly divided into four groups (n = 5). Group 1 received 10ml/kg distilled water, while Groups 2–4 received 250, 500 and 1000mg/kg (po) of the extract, respectively, for 28 days.

Results: Acute toxicity result showed no mortality in both phases of the study. In the sub-acute studies, significant increases in platelets in all treatment groups and RBC at the highest dose (1000 mg/kg) of the extract were observed (P < 0.05). There was a significant increase in sodium and potassium ions, while the liver function indices showed a significant elevation in alanine transaminase and aspartate transaminase at 500 and 1000mg/kg treatment doses. Histological examinations of the rat's kidney, liver, heart and spleen all showed normal cells; only follicular hyperplasia, congestion and oedema were seen in the spleen for groups treated with 500 and 1000mg/kg doses of the plant.

KEYWORDS:

ethnopharmacological; herbal vegetable; hepatotoxic; *Launaea taraxacifolia*; nephrotoxic; sub-acute toxicity study

ARTICLE HISTORY:

Received August 27, 2020
Accepted January 03, 2021
Published May 03, 2021

DOI:

10.5455/jcmr.2021.12.01.11

VOLUME: 12

ISSUE: 1

ISSN: 2146-8397

Conclusion: The aqueous leaf extract of *L. taraxacifolia* is relatively non-toxic. But can be hepatotoxic and nephrotoxic with long-term use of higher doses.

INTRODUCTION

The use and dependence on plants for food and medicinal purposes in developing economies such as in Africa and Asia are still high despite great strides achieved in orthodox medicines.¹ The World Health Organization (WHO) estimates that over 80% of the world's population, including the developed and developing countries, still rely on traditional medicines.¹⁻³ The use of herbal products for medicinal benefits still plays significant roles in many countries, including Nigeria.^{4,5} Notwithstanding many objections and warnings by WHO and health authorities due to lack of scientific and systematic validation of such remedies, traditional herbal remedies are still widely consumed and accepted in many African countries and other parts of the world.^{5,6} The food security in Africa is at a threat due to various political and calamities issues like drought due to global warming, increased cost of agricultural production, unstable pricing, internal/external conflicts and insecurities,^{7,8} hence necessitating the need for cheaper viable alternatives for food and medicines in the continent.

Launaea taraxacifolia (Willd.) is an economically viable vegetable plant with numerous ethnopharmacological potentials. It is cultivated in tropical Africa where it serves as food, medicine and fodder of animals.⁹ The plant has its origin in Ethiopian highlands and is a domesticated vegetable in Nigeria, Senegal and Benin.^{8,10} *L. taraxacifolia* is commonly called wild lettuce and has local Nigerian names such as “efo yanrin” in Yoruba, “ugu” in Igbo and “nonon barya” in Hausa.^{9,10} The plant is of high economic value due to its multiple uses. It is eaten as a vegetable because it is rich in proteins, essential fatty acids, vitamins, minerals and is highly fibrous. All of which significantly fill the nutrition deficiencies in the continent.^{7,9-11} The plant is also a potential source of medicines with various pharmacological properties including, anti-inflammatory, anti-nausea antibiotic, anti-anaemic, anti-poison, anti-venom, cholesterol reduction, sedative, anti-diabetic and anti-cough.^{8-10,12} Extract from the plant has also shown to have fungicidal and nematocidal properties.⁹ The ethnobotanical, phytochemical and pharmacological potentials of *L. taraxacifolia* is previously evaluated et al.⁸ Hence this study only aimed to investigate the acute and sub-acute toxicity of *L. taraxacifolia* (Willd.).

MATERIALS AND METHODS

PLANT COLLECTION AND EXTRACT PREPARATION

The leaf of *L. taraxacifolia* was collected from the medicinal plant garden of the Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, in February 2019. The

plant was identified and authenticated in the Department of Pharmacognosy and Ethnopharmacy, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria. A specimen with voucher number (PCG/UDUS/LLTF/0001) was deposited in the Departmental herbarium.

The study was carried out between February and September 2019. Extraction of *L. taraxacifolia* was performed according to a method already described by Alkali et al.¹³ The freshly collected were dried under the shade for 14 days. Five hundred grams of the dried plant was pulverised to powder form and subjected to 72 hours of cold maceration with distilled water. After maceration, the mixture was filtered using Whatman filter paper (size 1.5), concentrated in the water bath and oven-dried at 40. This dried extract was transferred into an airtight container and for further analysis.

EXPERIMENTAL ANIMALS

Adult Wistar rats of both sexes (weighing 120–170g) obtained from the Animal care facility of Ahmadu Bello University Zaria were used for the study. The animals were housed for one month under standard laboratory conditions (12 hours light/dark cycle, in a room temperature, maintained at 24) in the experimental animal handling facility of the Faculty of Pharmaceutical Science, Usmanu Danfodiyo University Sokoto. They were fed with a commercially available rat pelleted diet (livestock feed) with *ad libitum* access to water throughout the experiment. The study protocols were approved by the Institutional Animal Care and Use Committee, Department of Pharmacology and Toxicology, Usmanu Danfodiyo University, Sokoto. PTAC/Lt/(Ae)OT/33-21

ACUTE TOXICITY STUDY

Oral acute toxicity was studied using the method described elsewhere.¹⁴ This study was conducted in two phases. In the first phase, nine rats of both sexes fasted for 24 hours were randomly distributed into three groups with three rats each. Groups 1, 2 and 3 received 10, 100 and 1000mg/kg doses of the extract; were observed for 24 hours for any signs of toxicity and mortality. In the second phase, four rats were administered with 1200, 1600, 2900 and 5000mg/kg doses of the extract. The median lethal dose was determined by calculating the geometric mean of the highest dose that survived and the lowest dose that killed the animal.

SUB-ACUTE TOXICITY STUDY

The sub-acute toxicity profile was carried out using the Organisation for Economic Co-operation and Development 407 protocol.^{13,15} Twenty previously fasted (24 hours) Wistar albino rats were divided into four groups of 5 animals each, and the

following treatments were carried out once a day for 28 days orally:

- Group 1 (control): received 10 ml/kg/day of distilled water.
- Group 2: 250 mg/kg of the extract.
- Group 3: 500 mg/kg.
- Group 4: 1000 mg/kg.

The rats had *ad libitum* access to food and water throughout the experimental period; were observed daily for general symptoms of toxicity and mortality. The animals were euthanized on day 29 of the study. Before euthanasia, blood samples were collected by cardiac puncture for biochemical and haematological analysis. The heart, liver, kidney and spleen was excised and fixed with 10% formal saline for histopathological investigations.

HAEMATOLOGICAL INVESTIGATION

A portion of the collected blood stored in ethylenediamine-tetraacetic acid tubes was used to carry out the following haematological analysis in the department of Haematology Usmanu Danfodiyo University Teaching Hospital (UDUTH): white blood cell count (WBC) and differentials, haematocrit (HCT), haemoglobin (Hb), red blood cell count (RBC), mean corpuscular volume and platelet count.

BIOCHEMICAL INVESTIGATION

A portion of the blood sample previously collected and stored was subjected to the biochemical investigation such as liver function tests, determination of electrolytes, urea and creatinine parameters at the Specialist Hospital, Sokoto.

HISTOPATHOLOGICAL ASSESSMENT

The tissues (heart, liver, kidney and spleen) which were fixed were dehydrated in an ascending series of alcohol, cleared in xylene and embedded in paraffin wax melting at 60°C. The tissues were then cut into sections of 4–5 µm thick, stained with haematoxylin-eosin and observed under the microscope (Olympus BX41) at a magnification power of 100x.

Table 1 Oral acute toxicity of aqueous extract of *Launaea taraxacifolia* in rats.

Oral dose (mg/kg)	Number of rats dead/ Number of rats used	% mortality
PHASE I		
10	0/3	0
100	0/3	0
1000	0/3	0
PHASE II		
1600	0/1	0
2900	0/1	0
5000	0/1	0

STATISTICAL ANALYSIS

Results were expressed as the mean ± standard error of the mean. The difference between groups was determined by one-way analysis of variance (ANOVA) using statistical package for social sciences (SPSS, version 20.0) software for windows. *Post-hoc* test (Dunnett Multiple Comparison) for inter-groups was applied. Significance was considered at $p < 0.05$.

RESULTS

ACUTE TOXICITY STUDIES

The result of the acute toxicity is shown in Table 1. No mortality in both phases I and II was recorded.

HAEMATOLOGICAL INVESTIGATION

The effect of the aqueous leaf extract of *L. taraxacifolia* after 28 days of continuous oral administration showed a dose-dependent increase in WBC, RBC and Hb concentrations. The RBC count at 1000 mg/kg of the extract showed a statistically significant increase ($P < 0.05$). No statistically significant increases were recorded for the mean cell volume (MCV) as well as platelets count in the treatment groups versus control ($P < 0.05$; Figure 1).

RENAL FUNCTION INDICES

The effects of the *L. taraxacifolia* extract after 28 days of oral administration on the animal's electrolytes showed a dose-dependent increase in sodium ions which was statistically significant in the treatment groups versus control. There was a significant decrease in potassium ion concentrations in both 250 and 500 mg/kg does when compared to the control ($P < 0.05$) while the 1000 mg/kg caused a significant increase in potassium ion concentration ($P < 0.05$). The urea and bicarbonate concentrations were lower in the treatment groups versus control, while the chlorine levels were higher in the treated than the control (Table 2).

LIVER FUNCTION INDICES

The results showed a net reduction in total bilirubin (TB) and alkaline phosphatase (ALP) in all treatment groups. Increases




Figure 1 Effect of aqueous leaf extract of *Launaea taraxacifolia* (Willd) on haematological indices following 28 days of oral treatment in Wistar rats. *Statistically significant at $P > 0.05$.

Table 2 Effect of aqueous leaf extract of *Launaea taraxacifolia* (Willd) on renal function indices following 28 days oral treatment in Wistar rats.

Treatment group (mg/kg)	Urea (mmol/L)	Creatinine (mg/dl)	Sodium (mmol/L)	Potassium (mmol/L)	Chlorine (mmol/L)	Bicarbonate (mmol/L)
Distilled water	6.42 ± 0.17	1.12 ± 0.05	148.20 ± 1.35	5.72 ± 0.14	108.60 ± 1.20	25.60 ± 0.50
250	6.20 ± 0.10	1.26 ± 0.30	153.87 ± 0.58*	5.20 ± 0.07*	116.80 ± 0.96	25.00 ± 0.70
500	6.18 ± 0.80	1.08 ± 0.15	155.40 ± 0.50*	5.28 ± 0.12*	111.60 ± 2.15	25.40 ± 0.50
1000	6.34 ± 0.11	1.12 ± 0.06	162.80 ± 0.66*	6.46 ± 0.08*	112.00 ± 1.92	25.40 ± 1.02

* Statistically significant at $P > 0.05$.




Figure 2 Effect of aqueous leaf extract of *Launaea taraxacifolia* (Willd) on liver function indices following 28 days of oral treatment in Wistar rats. *Statistically significant at $P > 0.05$.

in aspartate transaminase (AST), alanine transaminase (ALT) and total protein versus control was recorded. Both AST and ALT were dose-dependent and significant ($P > 0.05$) at 500 and 1000 mg/kg. The albumin (ALB) showed a slight increase for the 250 and 1000 mg/kg, but a reduction for the 500 mg/kg versus control (Figure 2).

HISTOLOGICAL FINDINGS

Processed tissues in the kidney showed normal glomeruli, tubules and interstitium in all treatment groups (Figure 3). The liver assessment showed that all processed tissues had a normal portal triad, central vein and hepatocytes (Figure 4). The same result was observed in the heart tissues, as all treatment groups showed normal cardiac myocytes. However, microscopic examination of the spleen showed normal lymphoid follicles for the 250 mg/kg group. But sections of the groups treated with 500 and 1000 mg/kg showed follicular hyperplasia, congestion and oedema represented by a black arrow in Figure 5 (plate C and D, respectively).




Figure 3 Photomicrograph of a section of rat kidney treated with *Launaea taraxacifolia* (Willd) following 28 days of oral administration (H,E; 100x), distilled water (A), 250 mg/kg (B), 500 mg/kg (C) and 1000 mg/kg (D) extract treated groups.




Figure 4 Photomicrograph of a section of rat liver treated with *Launaea taraxacifolia* (Willd) following 28 days of oral administration (H and E, 100x) distilled water (A), 250 mg/kg (B), 500 mg/kg (C) and 1000 mg/kg (D) extract treated groups.




Figure 5 Photomicrograph of a section of rat spleen treated with *Launaea taraxacifolia* (Willd) following 28 days of oral administration (H and E, 100x), distilled water (A), 250 mg/kg (B), 500 mg/kg (C) and 1000 mg/kg (D) extract treated groups.

DISCUSSION

The top priority of any government is to provide food, security and health benefits for its citizens.⁷ The bioactive metabolites produced by plants are used as medicines for decades.^{3,16-18}

L. taraxacifolia is a herbal plant with economic and ethnobotanical potentials, and is easily domesticated.^{6,9} Several studies have investigated the nutritional and medicinal benefits of this plant and have reported that it contains flavonoids, saponins, phenol, ascorbic acid, phenol, oxalate and minerals such as calcium, manganese, selenium, potassium, magnesium, and zinc.^{6,19,20} The presence of the flavonoids and ascorbic demonstrate a strong antioxidant potential of the plant that if consumed, will over time help in evading off free radicals and also improve normal physiological and biological processes.^{5,16,21}

The acute toxicity of *L. taraxacifolia* showed no mortality in animals when used up to a dose of 5000 mg/kg of the extract. At this dose, a plant is usually presumed safe for oral consumption.^{15,17} In the 28 day's sub-acute toxicity study, no observable behavioural or toxic effects to the animals because of the administered extract indicates the relative safety of *L. taraxacifolia* throughout the study, even at the high dose of 1000 mg/kg.

The effect of *L. taraxacifolia* after the 28 days of oral administration showed a dose- dependent increase in WBC and RBC. Although this was not statistically significant except for RBC at the highest dose of 1000 mg/kg, suggesting a possible stimulation of erythropoietin.²²⁻²³ The increased WBC can be an indication of the immunity-boosting property of the plant. There was no significant change in Hb or HCT concentration. But a statistically significant increase in platelets count agreed with a previous study by Tohti et al.²⁴ The increase in platelets could have been due to the presence of some phytochemicals such as saponins and cardiac glycoside.²⁴⁻²⁶

The three divided doses of *L. taraxacifolia* used in this study (250, 500 and 1000 mg/kg) showed no significant changes in the urea, creatinine or carbonate levels in the animals following the 28 days of oral administration. Serum urea accumulation was used as a marker for acute renal injury, and serum creatinine accumulation was used in detecting chronic renal toxicity.^{13,27} The values of both creatinine and urea were lower or comparable with the control, pointing to the safety of *L. taraxacifolia* with regards to the kidneys, and histological findings showed no pathologies in the tissues examined. However, there was a statistically significant dose-dependent increase in sodium ion concentrations and a non-uniform effect on the potassium concentrations as a dose-dependent decrease was observed for 250 and 500 mg/kg groups, respectively, but a significant increase for the 1000 mg/kg dose. That indicated that the extract of *L. taraxacifolia* of different doses had minimal effect on the body's electrolytes but must be taken with caution in people with hypertension, potential for hypertension and prolonged extract use. The levels of AST, ALT and ALP are biomarkers for liver function or injury. The result of

this study reveals a significant increase in the level of AST and ALT, which was statistically significant at 500 and 1000 mg/kg doses indicating the possible hepatotoxic effect of the extract when compared with the control group, but there was a net decrease in ALP. The histology investigation of the rat's liver cells revealed no damage at the cellular level. The increases in AST and ALT was an indication of possible liver inflammatory potentials of *L. taraxacifolia* on chronic dosing longer than 28 days, although the presence of flavonoids and phenols compounds could mitigate this unwanted effect. Extract of LT has also been shown to normalized the lipid profile.²⁹

Histological examination of the tissues showed no cellular damage, except for the spleen tissue, indicating that *L. taraxacifolia* leaf extract can be relatively safe at low doses. Similar findings of an increase in serum concentration of ALT and ALP were reported by Peter et al.²⁸

The study of Isehunwa et al.⁴ showed that a dose of 200 mg/kg *L. taraxacifolia* extract significantly decreased the blood glucose and liver glycogen and increased muscle glycogen and lactate dehydrogenase activity after one week of administration, but was not seen post two weeks.^{4,30}

CONCLUSION

The acute and sub-acute toxicities of the leaf extract of *L. taraxacifolia* was evaluated orally and found to be safe. This study supports the use of *L. taraxacifolia* as a potential medicine and food. So the authors recommend the use and cultivation of the plant as a potential source for food security in the African continent.

FUNDING

The study was personally funded by the authors.

CONFLICT OF INTEREST

No potential conflict of interest was reported by the authors.

REFERENCES

1. World Health Organization. The selection and use of essential medicines. Report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children) WHO Technical Report Series No. 994. Geneva: World Health Organization; 2015.
2. Rickert K, Martinez RR, Martinez TT. Pharmacist knowledge of common herbal preparations. Proc West Pharmacol Soc. 1999;42:1-2.
3. Sofowora A. Medicinal plants and traditional medicine in Africa. Ibadan: Spectrum Books Ltd. 1993;191-289 pp.
4. Isehunwa G, Oluranti IO, Adewoye EO. Effects of aqueous extract of *Launaea taraxacifolia* leaf on glucose, glycogen levels and lactate dehydrogenase activity in male Wistar Rats. Arch Basic Appl Med. 2017; 5: 43-6.
5. Gidado A, Boonpisuttinank K, Kanjanawongwanich, S. Anti-cancer and anti-oxidative activities of Nigerian traditional medicinal plants/recipes. J Complement Med Res.. 2019;10(4): 200-11.

6. Gbadamosi IT, Alia AE, Okolosi O. In-vitro antimicrobial activities and nutritional assessment of roots of ten Nigerian vegetables. *New York Science Journal*. 2012; 5(12): 234–40.
7. Ozor N, Umunnakwe PC, Acheampong E. Challenges of food security in Africa and the way forward. *Development*. 2013; 56(3): 404–11.
8. Bello OM, Abiodun OB, Oguntoye SO. Insight into the ethnopharmacology, phytochemistry, pharmacology of *Launaea Taraxacifolia* (Willd) Amin Ex C. Jeffrey as an underutilized vegetable from Nigeria: A review. *Annals of the University Dunarea de Jos of Galati Fascicle VI – Food Technology*. 2018; 42(2): 137–52.
9. Obembe OO, Bello OA, Aworunse OS, Popoola JO, Akposibruke O, Olukanmi BI, Olayode MN. In vitro multiple shoots formation in wild lettuce (*Launaea taraxacifolia*) (Willd.) Amin ex C. Jeffrey. *Annu Res Rev Biol*. 2017;19(6): 1–8.
10. Adebisi AA. *Launaea taraxacifolia* (wild.) Amin ex C. Jeffrey. In: Grubben GJH, Denton OA, editors. *PROTA2: vegetables/legumes*. Wageningen, Netherlands: Prota; 2014..
11. Koukouli O, Senou M, Agbangnan P, Seton S, Koumayo F, Azonbakin S, et al. Effective in vivo cholesterol and triglycerides lowering activities of hydroethanolic extract of *Launaea Taraxacifolia* leaves. *Int J Pharm Sci Res*. 2017; 8: 2040–7.
12. Dickson RA, Anna K, Fleischer TC, Amponsah IK, Nsiah K, Oteng JA. Phytochemical investigations and nutritive potential of eight selected plants from Ghana. *J Pharm Nutr Sci*. 2012; 2(2), 172–7.
13. Alkali YI, Jimoh AO, Muhammad U. Acute and sub-chronic toxicity studies of methanol leaf extract of *Cassia singueana* F. (Fresen) in Wistar rats. *Herb Med*. 2018; 4(2):6.
14. Lorke DD. A new approach to acute toxicity testing. *Arch Toxicol*. 1983; 54: 275–83
15. OECD. Test No. 452. Chronic toxicity studies. OECD 76 guideline for testing chemicals. Available from: <https://www.oecd.org/env/test-no-452-chronic-toxicity-studies-9789264071209-en.htm>. [Accessed October 10, 2018]
16. Awodele O, Badru WA, Busari AA, Kale OE, Ajayi TB, Udeh RO, et al. Toxicological evaluation of therapeutic and supra-therapeutic doses of Cellgevity® on reproductive function and biochemical indices in Wistar rats. *BMC Pharmacol Toxicol*. 2018 Oct 25;19(1):68.
17. Kale OE, Awodele O, Akindele AJ. Subacute and subchronic oral toxicity assessments of *Acradocarpus smeathmannii* (DC.) Guill. & Perr. root in Wistar rats. *Toxicol Rep*. 2019 Jan 30;6: 161–75.
18. Umaru ML, Halilu EM, Uyaiabasi GN, Idris, B, Aliyu RB. In-vivo antiplasmodial activity of fractions of the aqueous and ethanolic extracts of stem bark of *Vitex doniana* on *Plasmodium berghei-berghei* infected mice. *Niger J Pharm Sci*. 2018; 3(3): 287–293.
19. Oduse KA, Idowu MA, Adegbite AA. Chemical and phytochemical profile of some uncommon green leafy vegetables consumed in South West, Nigeria. *IOSR J Environ Sci Toxicol Food Technol*. 2012; 1(3), 22–26.
20. Arawande JO, Amoo IA, Lajide L. Chemical and phytochemical composition of wild lettuce (*Launaea taraxacifolia*). *JAPES*. 2013; 2(1): 25–30.
21. Koukouli O, Senou M, Agbangnan P, Seton S, Koumayo F, Azonbakin S, et al. Effective in vivo cholesterol and triglycerides lowering activities of hydroethanolic extract of *Launaea Taraxacifolia* leaves. *Int J Pharm Sci Res*. 2017; 8(5), 2040–7.
22. Abubakar K, Danjuma NM, Maiha BB, Anuka JA, Yam MF, Shaibu B, et al. A 28 day oral toxicity study of *Pseudocedrela kotchyi* methanol extract in Sprague- Dawley rats. *Eur J Med Chem*. 2015;10: 1–11.
23. Sánchez-Elsner T, Ramírez JR, Sanz-Rodríguez F, Varela E, Bernabéu C, Botella LM. A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SP1 and Smads. *J MolBio*. 2004; 336(1), 9–24.
24. Tohti I, Tursun M, Umar A, Turdi S, Imin H, Moore H. Aqueous extracts of *Ocimum basilicum* L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin *in vitro* and rats arterio-venous shunt thrombosis *in vivo*. *ThrombRes*. 2006;118(6), 733–9.
25. Dairo JO, Ukpanukpong RU, Uyabeme RN. Phytochemical screening, proximate analysis and acute toxicity study of *Launaea Taraxacifolia* ethanolic extract on albino rats. *IJST*. 2015; 3: 199–202.
26. Adinortey MB, Sarfo JK, Quayson ET, Weremfo A, Adinortey CA, Ekloh W, et al. Phytochemical screening, proximate and mineral composition of *Launaea taraxacifolia* leaves. *Res J Med. Plant*. 2012; 6(2), 171–179.
27. Borges LP, Borges VC, Moro AV, Nogueira CW, Rocha JB, Gilson Zeni G. Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitro propane in rats. *Toxicology*. 2005; 210(1): 1–8. <https://doi.org/10.1016/j.tox.2005.01.002>.
28. Peter A, Njoku B, Kyrian UN. Effects of ethanolic extract of *Cyperus esculentus* (tiger nut) on some liver function parameters using albino Wistar rats. *Eur J Pharm Med Res*. 2015; 2(5):1705–15.
29. Salisu G, Titilola F, Okpuzor J, Jaja SI. Antilipidaemic studies of aqueous extracts of five selected Nigerian local edible vegetables in experimentally-induced myocardial infarction in male Wistar albino rats. In: Organization for women in science for the developing world (OWSD). Fifth General Assembly and International Conference on Women in Science and Technology for the Developing World, Kuwait.
30. Kpodar MS, Lawson-Evi P, Bakoma B, Eklu-Gadegbeku K, Agbonon A, Aklikokou K, et al. Ethnopharmacological survey of plants used in the treatment of diabetes mellitus in south of Togo (Maritime Region). *J Herb Med*. 2015; 5(3):147–152.